Figure 1.
Patient disposition.aDid not discontinue from the study prematurely. Patients who discontinued participation in the study because the study was stopped were considered to have completed the study. bPatients were discontinued because of central laboratory results indicating baseline FIX activity level >2%. cPatient was discontinued because of site closing. dPatient was withdrawn from the study because of treatment-emergent serious adverse event (TESAE) of hypersensitivity and FIX inhibition, which were considered related to study treatment.

Patient disposition.aDid not discontinue from the study prematurely. Patients who discontinued participation in the study because the study was stopped were considered to have completed the study. bPatients were discontinued because of central laboratory results indicating baseline FIX activity level >2%. cPatient was discontinued because of site closing. dPatient was withdrawn from the study because of treatment-emergent serious adverse event (TESAE) of hypersensitivity and FIX inhibition, which were considered related to study treatment.

Close Modal

or Create an Account

Close Modal
Close Modal